Pharmacists stockpile most common drugs on chance of targeted Trump tariffs
Prescription drugs sit ready to be distributed to patients at 986 Pharmacy in Alhambra, California. (Jackie Fortíer/KFF Health News)
In the dim basement of a Salt Lake City pharmacy, hundreds of amber-colored plastic pill bottles sit stacked in rows, one man's defensive wall in a tariff war.
Independent pharmacist Benjamin Jolley and his colleagues worry that the tariffs, aimed at bringing drug production to the United States, could instead drive companies out of business while raising prices and creating more of the drug shortages that have plagued American patients for several years.
Jolley bought six months' worth of the most expensive large bottles, hoping to shield his business from the 10% across-the-board tariffs on imported goods that President Donald Trump announced April 2. Now with threats of additional tariffs targeting pharmaceuticals, Jolley worries that costs will soar for the medications that will fill those bottles.
In principle, Jolley said, using tariffs to push manufacturing from China and India to the U.S. makes sense. In the event of war, China could quickly stop all exports to the United States.
'I understand the rationale for tariffs. I'm not sure that we're gonna do it the right way,' Jolley said. 'And I am definitely sure that it's going to raise the price that I pay my suppliers.'
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Squeezed by insurers and middlemen, independent pharmacists such as Jolley find themselves on the front lines of a tariff storm. Nearly everyone down the line — drugmakers, pharmacies, wholesalers, and middlemen — opposes most tariffs.
Slashing drug imports could trigger widespread shortages, experts said, because of America's dependence on Chinese- and Indian-made chemical ingredients, which form the critical building blocks of many medicines. Industry officials caution that steep tariffs on raw materials and finished pharmaceuticals could make drugs more expensive.
'Big ships don't change course overnight,' said Robin Feldman, a UC Law San Francisco professor who writes about prescription drug issues. 'Even if companies pledge to bring manufacturing home, it will take time to get them up and running. The key will be to avoid damage to industry and pain to consumers in the process.'
Trump on April 8 said he would soon announce 'a major tariff on pharmaceuticals,' which have been largely tariff-free in the U.S. for 30 years.
'When they hear that, they will leave China,' he said. The U.S. imported $213 billion worth of medicines in 2024 — from China but also India, Europe, and other areas.
Trump's statement sent drugmakers scrambling to figure out whether he was serious, and whether some tariffs would be levied more narrowly, since many parts of the U.S. drug supply chain are fragile, drug shortages are common, and upheaval at the FDA leaves questions about whether its staffing is adequate to inspect factories, where quality problems can lead to supply chain crises.
Private equity snaps up disability services, challenging state regulators
On May 12, Trump signed an executive order asking drugmakers to bring down the prices Americans pay for prescriptions, to put them in line with prices in other countries.
Meanwhile, pharmacists predict even the 10% tariffs Trump has demanded will hurt: Jolley said a potential increase of up to 30 cents a vial is not a king's ransom, but it adds up when you're a small pharmacy that fills 50,000 prescriptions a year.
'The one word that I would say right now to describe tariffs is 'uncertainty,'' said Scott Pace, a pharmacist and owner of Kavanaugh Pharmacy in Little Rock, Arkansas.
To weather price fluctuations, Pace stocked up on the drugs his pharmacy dispenses most.
'I've identified the top 200 generics in my store, and I have basically put 90 days' worth of those on the shelf just as a starting point,' he said. 'Those are the diabetes drugs, the blood pressure medicines, the antibiotics — those things that I know folks will be sicker without.'
Pace said tariffs could be the death knell for the many independent pharmacies that exist on 'razor-thin margins' — unless reimbursements rise to keep up with higher costs.
Unlike other retailers, pharmacies can't pass along such costs to patients. Their payments are set by health insurers and pharmacy benefit managers largely owned by insurance conglomerates, who act as middlemen between drug manufacturers and purchasers.
Neal Smoller, who employs 15 people at his Village Apothecary in Woodstock, New York, is not optimistic.
'It's not like they're gonna go back and say, well, here's your 10% bump because of the 10% tariff,' he said. 'Costs are gonna go up and then the sluggish responses from the PBMs — they're going to lead us to lose more money at a faster rate than we already are.'
Smoller, who said he has built a niche selling vitamins and supplements, fears that FDA firings will mean fewer federal inspections and safety checks.
'I worry that our pharmaceutical industry becomes like our supplement industry, where it's the wild West,' he said.
Narrowly focused tariffs might work in some cases, said Marta Wosińska, a senior fellow at the Brookings Institution's Center on Health Policy. For example, while drug manufacturing plants can cost $1 billion and take three to five years to set up, it would be relatively cheap to build a syringe factory — a business American manufacturers abandoned during the covid-19 pandemic because China was dumping its products here, Wosińska said.
It's not surprising that giants such as Novartis and Eli Lilly have promised Trump they'll invest billions in U.S. plants, she said, since much of their final drug product is made here or in Europe, where governments negotiate drug prices. The industry is using Trump's tariff saber-rattling as leverage; in an April 11 letter, 32 drug companies demanded European governments pay them more or face an exodus to the United States.
Brandon Daniels, CEO of supply chain company Exiger, is bullish on tariffs. He thinks they could help bring some chemical manufacturing back to the U.S., which, when coupled with increased use of automation, would reduce the labor advantages of China and India.
'You've got real estate in North Texas that's cheaper than real estate in Shenzhen,' he said at an economic conference April 25 in Washington, referring to a major Chinese chemical manufacturing center.
Despite historic indictment, doctors will keep mailing abortion pills across state lines
But Wosińska said no amount of tariffs will compel makers of generic drugs, responsible for 90% of U.S. prescriptions, to build new factories in the U.S. Payment structures and competition would make it economic suicide, she said.
Several U.S. generics firms have declared bankruptcy or closed U.S. factories over the past decade, said John Murphy, CEO of the Association for Accessible Medicines, the generics trade group. Reversing that trend won't be easy and tariffs won't do it, he said.
'There's not a magic level of tariffs that magically incentivizes them to come into the U.S.,' he said. 'There is no room to make a billion-dollar investment in a domestic facility if you're going to lose money on every dose you sell in the U.S. market.'
His group has tried to explain these complexities to Trump officials, and hopes word is getting through. 'We're not PhRMA,' Murphy said, referring to the powerful trade group primarily representing makers of brand-name drugs. 'I don't have the resources to go to Mar-a-Lago to talk to the president myself.'
Many of the active ingredients in American drugs are imported. Fresenius Kabi, a German company with facilities in eight U.S. states to produce or distribute sterile injectables — vital hospital drugs for cancer and other conditions — complained in a letter to U.S. Trade Representative Jamieson Greer that tariffs on these raw materials could paradoxically lead some companies to move finished product manufacturing overseas.
Fresenius Kabi also makes biosimilars, the generic forms of expensive biologic drugs such as Humira and Stelara. The United States is typically the last developed country where biosimilars appear on the market because of patent laws.
Louisiana considers 'homelessness courts' as housing advocates stress lack of resources
Tariffs on biosimilars coming from overseas — where Fresenius makes such drugs — would further incentivize U.S. use of more expensive brand-name biologics, the March 11 letter said. Biosimilars, which can cost a tenth of the original drug's price, launch on average 3-4 years later in the U.S. than in Canada or Europe.
In addition to getting cheaper knockoff drugs faster, European countries also pay far less than the United States for brand-name products. Paradoxically, Murphy said, those same countries pay more for generics.
European governments tend to establish more stable contracts with makers of generics, while in the United States, 'rabid competition' drives down prices to the point at which a manufacturer 'maybe scrimps on product quality,' said John Barkett, a White House Domestic Policy Council member in the Biden administration.
As a result, Wosińska said, 'without exemptions or other measures put in place, I really worry about tariffs causing drug shortages.'
Smoller, the New York pharmacist, doesn't see any upside to tariffs.
'How do I solve the problem of caring for my community,' he said, 'but not being subject to the emotional roller coaster that is dispensing hundreds of prescriptions a day and watching every single one of them be a loss or 12 cents profit?'
SUPPORT: YOU MAKE OUR WORK POSSIBLE
This article first appeared on KFF Health News and is republished here under a Creative Commons license. KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF and subscribe to KFF Health News' free Morning Briefing.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Investors Rush to Pour Cash Into $7.4 Trillion US Money-Market Fund Industry
(Bloomberg) -- The rush of cash into the US money-market funds is showing few signs of slowing as it secured a record $7.4 trillion in assets. Bezos Wedding Draws Protests, Soul-Searching Over Tourism in Venice One Architect's Quest to Save Mumbai's Heritage From Disappearing NYC Congestion Toll Cuts Manhattan Gridlock by 25%, RPA Reports Investors have poured more than $320 billion into the funds so far this year, according to Crane Data LLC, making it one of the biggest benefactors of the Federal Reserve's current monetary policy. That's something of a surprise for those on Wall Street who'd gone into 2025 assuming officials would lower interest rates and sap the attractive returns offered by the industry. '$7 trillion can easily be $7.5 trillion in 2025,' said Deborah Cunningham, chief investment officer for global liquidity markets at Federated Hermes. 'Five-percent-plus rates were nirvana, four-percent-plus is still very good — and if we dip down into the high threes, that's quite acceptable as well.' The average simple seven-day yield is now 3.95% for government funds and 4.03% for prime, an 8 basis point spread, according to Bank of America Corp. It's a compelling backdrop as some 600 participants gather at the annual Crane's Money Fund Symposium, which kicks off Monday in Boston. Money funds have seen their coffers swell in recent years, notably in early 2020 for their haven appeal and again as the Fed's rate-hiking cycle boosted yields. Even as the Fed pivoted to cutting rates last year, assets continued to rise, with these funds typically slower to pass along the effects of lower rates when compared to banks. Households have been a key driver of the inflows. Since the Fed started raising rates in March 2022, total assets under management in US money funds have swelled by roughly $2.5 trillion, and retail investors have accounted for about 60% of that, Investment Company Institute data show. Data from ICI exclude firms' own internal money funds, unlike Crane Data, which tracks the money market industry. Inflows have continued even as the industry sees some investors embrace alternatives, such as ultra-short funds in the fixed income or equities, Cunningham said. Overall, though, it's a far cry from the exodus of cash from money-market funds that some on Wall Street had forecast. 'It's not surprising asset levels have held on and grown,' said Michael Bird, senior fund manager at Allspring Global Investments. 'Even if the Fed picks up its easing campaign this year, rates will still be relatively high.' The Fed last week laid out forecasts for two quarter-point rate cuts this year, aligning with market pricing. Although the risk that conflict in the Middle East drives up oil prices and causes a resurgence in inflation remains an uncertatinty, traders see a quarter-point reduction as likely in September and all but guaranteed by October. Given that interest-rate backdrop, money-market funds are trying to extend the weighted-average maturity — known as WAM — of their holdings as long as possible to capture elevated yields. Fund managers have also adjusted holdings to compensate for the effects of debt-ceiling drama. While Wall Street strategists largely expect the government to raise the debt limit as part of the reconciliation process by late of July or early August, some funds have put more cash toward repurchase agreements — loans collateralized by Treasuries or agency debt — as an alternative. Still, 'the expectation is when the debt ceiling gets resolved, there will be a significant increase in bill issuance, which helps yields,' Bird said. 'Uncertainty is helping our product.' Luxury Counterfeiters Keep Outsmarting the Makers of $10,000 Handbags Is Mark Cuban the Loudmouth Billionaire that Democrats Need for 2028? Ken Griffin on Trump, Harvard and Why Novice Investors Won't Beat the Pros The US Has More Copper Than China But No Way to Refine All of It Can 'MAMUWT' Be to Musk What 'TACO' Is to Trump? ©2025 Bloomberg L.P.
Bloomberg
24 minutes ago
- Bloomberg
The Budget Bill Is Creating a Republican Existential Crisis
The Republican budget bill, a $3.7 trillion tax cut packaged with $1.2 trillion in spending cuts, is deeply problematic legislation from almost any perspective — including those of its authors. The Congressional Budget Office has the details about how it will be expensive and ineffectual. But for Republicans, President Donald Trump's 'big, beautiful bill' is creating what amounts to an existential crisis. For half a century, Republicans have been committed to the policy of lower taxes to aid the economy — impervious to any evidence that tax cuts are inefficient and prohibitively expensive. At this point, to walk away from the bill is to abandon their economic raison d'etre.
Bloomberg
24 minutes ago
- Bloomberg
Bloomberg Surveillance TV: June 23, 2025
- Norman Roule, Senior Adviser at the Center for Strategic & International Studies - Daan Struyven, Head: Commodity Research at Goldman Sachs - Mark Esper, former US Secretary of Defense - Danny Danon, Israel's Ambassador to the United Nations Norman Roule, Senior Adviser at the Center for Strategic & International Studies, discusses the US strikes on Iran and what's next for conflict in the Middle East. Daan Struyven, Head: Commodity Research at Goldman Sachs, offers his outlook for oil and global commodities in the wake of the US' attack on Iran. Mark Esper, former US Secretary of Defense, talks about the strategy aimed at weakening Iran's nuclear capabilities and whether early indications show the US achieved its objectives. Danny Danon, Israel's Ambassador to the United Nations, talks about Israel's position in the Middle East after the US' strike on Iran.
